NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today that its fully owned subsidiary Pluristem Ltd has received a competitive research and development grant of about $830,000 from Israel’s prestigious Chief Scientist Office (CSO).
